Fred R Hirsch, MD, PhD
img_Fred R Hirsch
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Lung Cancer
Research Focus Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.

MD, University of Copenhagen

PhD, University of Copenhagen

BA, University of Copenhagen Business School

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Hirsch during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Gerson Lehrman Group
  • NextCure

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose

  • MJH Life Sciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.